Molecular modelling leads the way in drugs discovery research
15 Jan 2000
Despite the growing interest in simulation modelling for designing pharmaceuticals plants, the industry's main use for software remains in molcular modelling as a drug discovery tool. Recent business deals include a three-year collaboration between Ribo Targets, a Cambridge-based company which focuses on drugs which bind to RNA, with US-based Molecular Simulations.
Ribo Targets uses NMR to determine the structure of specific RNA fragments, and aims to design drugs which stop the RNA from replicating. Molecular Simulations is to develop software that will model both the RNA target and the drug active molecule.
